Paclitaxel - Oasmia Pharmaceutical

Drug Profile

Paclitaxel - Oasmia Pharmaceutical

Alternative Names: Apealea; OAS-PAC-100; Paclical; Paclitaxel micellar - Oasmia Pharmaceuticals; Paclitaxel-XR-17; XR-17-paclitaxel

Latest Information Update: 25 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oasmia Pharmaceutical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Registered Ovarian cancer
  • Preregistration Fallopian tube cancer; Peritoneal cancer
  • No development reported Breast cancer

Most Recent Events

  • 21 Sep 2018 Committee for Medicinal Products for Human Use (CHMP) recommends approval of Paclitaxel for Ovarian cancer, Fallopian tube cancer, Peritoneal cancer (Combination therapy, Second-line therapy or greater) in European Union
  • 21 Sep 2018 Updated Efficacy and safety data from the phase III OAS-07OVA trial in Ovarian cancer released by Oasmia Pharmaceutical
  • 27 Jul 2018 Committee for Orphan Medicinal Products (COMP) reviews the orphan drug designation for paclitaxel for Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top